Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1882099
Biomarkers - Global Strategic Business Report
Description:
This report analyzes the worldwide markets for Biomarkers in US$ Million by the following Technologies and Services: Technologies - Emerging Biomarker Technologies (Imaging biomarkers, Proteomics, Transcriptomics, & Bioinformatics), Conventional Biomarker Technologies - (Immunodiagnostics, & Molecular Diagnostics), and Others; Services - Clinical Biomarker Services, Specimen Preparation, and Bioinformatics and Others (miRNA Analysis and Others).
The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular). Key Therapeutic Areas also analyzed in the report include Oncology, Cardiology, CNS, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017.
The report profiles 204 companies including many key and niche players such as
- Abbott Laboratories
- Affymetrix Inc.
- Agilent Technologies Inc.
- Alexion Pharmaceuticals
- Beckman Coulter Inc.
- Becton
- Dickinson and Company
- Bio-Rad Laboratories Inc.
- BioMérieux
- Bruker Corporation
- Caprion Proteomics Inc.
- Clarient Inc.
- Compugen Ltd.
- Correlogic Systems Inc.
- DiagnoCure Inc.
- Epigenomics AG
- GE Healthcare
- Gene Logic
- Genedata AG
- Gen-Probe Inc.
- GlaxoSmithKline Plc
- Hitachi Medical Corporation
- Illumina Inc.
- LabCorp.
- Life Technologies Corporation
- Merck & Co. Inc.
- Metabolon Inc.
- Myriad Genetics Inc.
- Novartis International AG
- Panacea Laboratories
- Pfizer Inc.
- Philips Healthcare
- QIAGEN NV
- Quest Diagnostics Inc.
- Roche Diagnostics Corp.
- Rubicon Genomics Inc.
- Rules-Based Medicine Inc.
- Siemens Healthcare Diagnostics Inc.
Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular). Key Therapeutic Areas also analyzed in the report include Oncology, Cardiology, CNS, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017.
The report profiles 204 companies including many key and niche players such as
- Abbott Laboratories
- Affymetrix Inc.
- Agilent Technologies Inc.
- Alexion Pharmaceuticals
- Beckman Coulter Inc.
- Becton
- Dickinson and Company
- Bio-Rad Laboratories Inc.
- BioMérieux
- Bruker Corporation
- Caprion Proteomics Inc.
- Clarient Inc.
- Compugen Ltd.
- Correlogic Systems Inc.
- DiagnoCure Inc.
- Epigenomics AG
- GE Healthcare
- Gene Logic
- Genedata AG
- Gen-Probe Inc.
- GlaxoSmithKline Plc
- Hitachi Medical Corporation
- Illumina Inc.
- LabCorp.
- Life Technologies Corporation
- Merck & Co. Inc.
- Metabolon Inc.
- Myriad Genetics Inc.
- Novartis International AG
- Panacea Laboratories
- Pfizer Inc.
- Philips Healthcare
- QIAGEN NV
- Quest Diagnostics Inc.
- Roche Diagnostics Corp.
- Rubicon Genomics Inc.
- Rules-Based Medicine Inc.
- Siemens Healthcare Diagnostics Inc.
Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Contents:
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 2
Quantitative Techniques & Analytics 3
Product Definition and Scope of Study 3
Definitions 4
Biomarker Technologies 4
Emerging Biomarker Technologies 4
Proteomics 4
Transcriptomics 5
Imaging biomarkers 5
Bioinformatics 5
Conventional Biomarker Technologies 5
Molecular Diagnostics 5
Immunodiagnostics 6
Other Biomarker Technologies 6
Metabolite and Enzyme Assays 6
Reagents 6
Biomarker Services 6
Clinical Biomarker Services 6
Biomarker Testing 6
Assay Development and Production 6
Antibody Development 7
Specimen Preparation 7
Bioinformatics and Others 7
2. INDUSTRY OVERVIEW 8
Global Biomarkers Market Surges in the Backdrop of Widening
Medical Scope and Applications 8
Factors Engendering Positive Vibes 8
Factors Engendering Positive Influence on the Biomarkers
Market: A Summary 9
Biomarkers: A Regional Perspective 9
US Spearheads the Global Biomarkers Market 9
US and Japan Take Lead on the Patent Front 10
Table 1: Dominance of US in the Global Biomarker Patent
Filings (includes corresponding Graph/Chart) 10
Table 2: Leading Players in the Biomarkers Space by Number
of Patent Filings (includes corresponding Graph/Chart) 11
Table 3: Number of Biomarker Patents Published and Filed:
2003-2007 (includes corresponding Graph/Chart) 11
Asia-Pacific: The Fastest Growing Biomarker Market 12
Supportive Governments and Regulatory Bodies to Fuel Growth 12
Increasing Collaborations Among Regulators and Companies
Augur Well for Biomarkers 12
Player Strategies: An Insight 13
Table 4: Growing Number of Biomarker Deals (includes
corresponding Graph/Chart) 13
Table 5: Competitive Strategy Mix in the Global Oncology
Biomarkers Market (includes corresponding Graph/Chart) 14
Pharma and Biomarker Developer Tie-Ups to Raise Drug
Development Productivity 14
3. MARKET OUTLOOK 15
Biomarkers: Evolving Scope and Applications 15
Technological Advancements - A Boon for Biomarker Discovery 15
Evolving Role of Biomarkers in Drug Development 16
Companion Biomarkers 16
Biomarkers Play Invaluable Role in Oncology and Cardiovascular
Disease Diagnosis 16
Personalized Medicine- Revolutionizing the Medical Treatment 17
Biomarker-Led Drug Discovery - A Profitable Investment 18
Technological Trends 18
Proteins Gain Upper Hand in Biomarkers 18
Mass Spectrometry - A Promising Technology in Molecular Medicine 18
Market Restraints 19
Challenges in Biomarker Validation - A Major Growth Retardant 19
The Road Ahead 19
Biomarkers to Witness Significant Growth in Therapeutic and
Diagnostic Arenas 19
Efficiency Improvements Must for Realizing Cost-Effective
Biomarker Testing 20
4. BIOMARKER TECHNOLOGIES AND SERVICES: AN OVERVIEW 21
Biomarker - Definition & Introduction 21
BIOMARKER TECHNOLOGIES 21
EMERGING BIOMARKER TECHNOLOGIES 21
Proteomics 22
Growth Drivers and Market Trends 22
Efficiency Gains in Drug Discovery Drive Growth in Proteomics 22
Proteomics Witness Increased Focus on Targeted Approach 22
Mass Spectrometry -Shifts in Focus to Proteomics Helps
Biomarker Development 23
Mass Spectrometry Expands Scope of Protein Biomarker
Applications 23
Transcriptomics 23
Transcriptomics - Assisting in Identification of Biomarkers 23
Imaging Biomarkers: Disease Diagnosis, the Non-Invasive way 24
Types of Imaging Biomarkers - An Overview 24
Market Trends 25
Molecular Imaging - Gaining Importance in Drug Discovery
and Development 25
Use of Molecular Imaging in Clinical Trials for Drug
Development 25
Bioinformatics 26
CONVENTIONAL BIOMARKER TECHNOLOGIES 26
Molecular Diagnostics 26
Immunodiagnostics 26
Market Trends 26
Growth in Use of Molecular Diagnostics to Propel Biomarker
Growth 26
Demand for Novel Biomarkers Persists in Immunodiagnostics 27
Immunoassays Plagued with Standardization Issues 27
OTHER BIOMARKER TECHNOLOGIES 27
Metabolite and Enzyme Assays 27
Reagents 28
Market Trends 28
Microarrays Surge Biomarker Identification 28
Metabolomics Gain Rapid Foothold in Drug Discovery 28
BIOMARKER SERVICES 28
Expanding Capabilities Drive Large-Scale Adoption 29
Clinical Biomarker Services 29
Biomarker Testing 29
Assay Development and Production 30
Antibody Development 30
Specimen Preparation 30
Bioinformatics and Other Biomarker Services 31
Bioinformatics Gain Prominence 31
miRNA Analysis 31
Microarray Services Witness Increasing Investments 31
5. BIOMARKERS MARKET BY APPLICATION 32
Role of Biomarkers in Drug Discovery and Development 32
Role of Biomarkers in Clinical Research and Patient Management 32
Major Benefits of Biomarkers in Clinical Development 33
Major Benefits of Biomarkers in Medicine 33
Multifarious Applications of Biomarkers 33
New Applications Come to the Fore 33
Application of Biomarkers in Drug Development 34
Herceptin and Vilazodone -References for Success of Biomarker
Based Approach 34
Increasing Role of Biomarkers in Modern Drug R&D 35
Translational Medicine Biomarkers Revolutionizing Drug
Development Process 35
Outsourcing - Opportunities Galore 35
CROs in a Dilemma Over Investments in Biomarker Analysis
Services 36
Lower Productivity of Traditional Drug Discovery Approach
Calls for New Methods 36
Blockbuster Model Versus Personalized Medication Model 37
Workflow Standardization - Key to Success of Biomarkers in
Drug Development 37
6. BIOMARKERS BY THERAPEUTIC AREA 38
Current & Future Analysis 38
ONCOLOGY 38
Factors Driving Oncology Biomarkers' Growth 38
US Remains at the Forefront of Cancer Biomarker Patent Filings 39
Table 6: Regional Split in the Global Cancer Biomarker
Patent Filings: 2009 (includes corresponding Graph/Chart) 39
Table 7: Leading Players in Cancer Biomarkers by Number of
Patent Filings: 2004-2009 39
Global Oncology Diagnostics and Drug Discovery Biomarkers Market 40
Table 8: World Recent Past, Current and Future Analysis for
Oncology Biomarkers Market by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 41
Table 9: World 10-Year Perspective for Oncology Biomarkers
Market by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest
of World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 42
Table 10: Global Cancer Biomarkers Diagnostics (Molecular)
Market by Company (2009): Market Share Breakdown of Revenues
for Roche, Gen-Probe, Myriad, Abbott, QIAGEN and Others
(includes corresponding Graph/Chart) 43
Evolution of Oncology Biomarkers 43
Available and Pipeline Biomarkers in Various Cancers 44
Breast Cancer Dominates Cancer Biomarkers Pipeline 44
Table 11: Global Cancer Biomarkers Pipeline by Indication
(2010): Percentage Share Breakdown for Breast Cancer,
Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and
Others (includes corresponding Graph/Chart) 45
Table 12: Global Oncology Biomarkers Market: Percentage
Breakdown of Patent Filings by Oncology Area (2007) 45
Breast Cancer Market Awaits New Specific Biomarkers 45
Oncology Biomarker Diagnostic Techniques 46
Table 13: Leading Cancer Biomarker Diagnostic Technologies
(2009): Percentage Share of Value Sales for Gene-based
Markers, Proteomics, DNA Microarrays, Immunological Markers
and IHC Tests, and Others (includes corresponding
Graph/Chart) 46
Current Trends in Cancer Biomarkers 47
Validation Techniques Take Center Stage 47
Early-Stage Use of Biomarkers High in Oncology 47
Proteomics Ahead of Genomic Biomarkers in Functionality 48
Pharmacogenomics and IHC Tests Inch Ahead in Cancer
Biomarker Diagnostics 48
Faster Diagnosis Benefits DNA Microarray Technology 48
Other Tests Lose Market Share 49
Companion Biomarkers in Oncology 49
CARDIOLOGY 49
Market Trends 50
Increasing Health Burden Drives Research Efforts 50
Gene Expression Analysis Delivers Novel Therapeutic Approaches 50
High-Performance Techniques Drive Biomarker Discovery in
Cardiology 51
Effective Phenotyping Takes Precedence for Successful
Genotyping Studies 51
Role of Linkage Analysis in Cardiovascular Biomarker
Identification 51
Biomarkers of ACS 51
Biomarkers - A Promising Diagnostic Tool for ACS 52
Biomarker Discovery in Cardiovascular Diseases to Undergo
Significant Changes 52
Major Cardiovascular Diagnostic Biomarkers - A Focus on
Biomarkers for ACS 53
Creatine Kinase-Myocardial Band 53
Natriuretic Peptides 53
Cardiac Troponin 53
Myoglobin 53
New Diagnostic Biomarkers for ACS on the Anvil 54
Genomic Biomarkers for Detecting Cardiovascular Diseases 54
Growing Demand for Stroke Biomarkers 55
Rising Incidence of the Disease - A Major Driver for Stroke
Biomarkers 55
CENTRAL NERVOUS SYSTEM (CNS) 55
Lower Commercial Availability Restricts Market Share 56
Research Efforts Remain Confined to Specific Areas 56
High Cost of Treatment Shadows Biomarkers' Short-Treatment
Benefits 56
Research Methodology in CNS Biomarkers 56
Alliances - A Key Aspect to the Development of CNS Biomarkers 57
Biomarkers in Select CNS Diseases 57
Alzheimers Disease 57
Parkinsons Disease Biomarkers - Crucial for
Neuroprotectants' Effectiveness 58
Schizophrenia: An Unexploited Segment 58
OTHER THERAPEUTIC AREAS 58
Inflammatory and Autoimmune Disorders 58
Biomarkers offer Efficient Diagnosis and Treatment 59
Rheumatology 59
7. AN OVERVIEW OF SELECT BIOMARKERS 60
HER2/neu/ ErbB2 Gene 60
HER2 and its Association with Cancer 60
Target Drugs for HER2 60
Hepsin Biomarkers 60
Early Prostate Cancer Antigen-2 60
MMP-3 61
ImmunoCyt™/uCyt+™ 61
AmpliChip CYP450 Test 62
The OncoVue® Breast Cancer Risk Test 62
Oncotype DX® Test 62
Oncotype DX Colon Cancer Assay 63
MammaPrint 63
Theros CancerTYPE ID 63
PgxPredict:CLOZAPINE- Test for Qualifying Patients to Use
Clozapine 63
The Pathwork Tissue of Origin Test 64
PROGENSA PCA3 Assay 64
Epi proColon® Early Detection Assay 64
OVA1® Test 65
Bcr-abl Fusion Protein 65
HLA-B 65
Mammostrat® 65
Ipsogen MapQuant Dx™ Genomic Grade 66
CA1-18 Enzyme Immunoassay (EIA) 66
Anti-L523S Antibody 66
8. PRODUCT INTRODUCTIONS IN THE BIOMARKERS SPACE 67
RBM Unveils OncologyMAP® Panel of 101 Quantitative Biomarker
Tests 67
Avantra Introduces New BioChip Immunoassay Biomarker Workstation 67
Clarient Introduces Mammostrat Test 67
Biomagnetics Diagnostics Identifies Second Biomarker for
Tuberculosis Assay 68
Epistem Introduces Novel Ex Vivo Plucked Hair Biomarker Assay 68
Crescendo Bioscience Launches New Multi Biomarker Blood Test 68
Alere International Launches New Triage® NT-proBNP Test 68
Agilent Technologies Launches New SureSelect Kinome Target
Enrichment Kit 69
Roche Diagnostics to Launch New STAT Immunoassays 69
Gentel Biosciences Launches New Human Profiling Kits 69
QIAGEN Introduces QIAsymphony RGQ System 70
Almac Introduces Biomarkers for Biopharmaceutical Industry 70
i-Path Introduces TMA Toolbox 71
Abbott Introduces ARCHITECTPLUS Systems 71
Affymetrix Introduces QuantiGene® ViewRNA Assayformats 72
ARUP Laboratories Introduces New Test for Colorectal Caner
Detection 72
Warnex Launches Blood Testing Service for Colorectal Cancer in
Canada 72
Agilent Technologies Launches mAb-Glyco-Chip 73
synlab Launches Septin9 Testing in Germany 73
IDBS Introduces New Biomarker Discovery and Validation Solution 73
Quest Diagnostics Introduces Blood Test for Detecting
Colorectal Cancer 74
Clarient Introduces Biomarker Panel for NSCLC Classification 74
Institute of Microelectronics and Agency for Science,
Technology and Research Launch Rapid Cardiac Biomarker Test 74
Rules-Based Medicine Unveils CardiovascularMAP™ for CVD Treatment 75
Thermo Fisher Introduces New Copeptin Assay 75
Psynova Neurotech and RBM Identify New Biomarkers for
Schizophrenia 75
Genedata Unveils Genedata Expressionist® 5.3 75
Arrayit Introduces Biomarker Discovery Service 76
Invitrogen Introduces Biomarker Tool for Kidney Function Research 76
Abbott Introduces ARCHITECT® c4000® 76
Epigenomics Rolls Out Epi proColon Range in Europe 77
Genedata Introduces Expressionist 5.2 for Identifying MS-based
Biomarker 77
VisEn Unveils FAST - A Novel Imaging Platform 77
Millipore and CXR Biosciences Unveils ToxReporter™ 78
Rules-Based Medicine Unveils Human Kidney Multi-Analyte Profile 78
MDS and Applied Biosystems Launch AB SCIEX TOF/TOF™ 5800 System 78
Genetic Biomarkers for Chronic Kidney Disease 79
Bruker Launches Advanced MALDI-TOF/TOF Mass Spectrometer 79
Satoris Introduces three Novel Blood Tests 79
GE Healthcare Launches Discovery™ MR450 79
GE Healthcare in Partnership with Varian Launches Discovery
MR901 (US) 80
Applied Biosystems and MDS Analytical Launches Novel New Mass
Spectrometry Tools 80
Rules-Based Medicine Commercializes Rat Kidney MAP Biomarker
Panel 80
Thomson Reuters Introduces BIOMARKERcenter 81
Gentel® Biosciences Introduces SilverQuant™ GlycoBiomarker
Array Kit 81
BioMarker Pharmaceuticals Introduces Gene Essence™ DNA Test 82
mtm laboratories Introduces Cervatec™ Assay 82
Decision Biomarkers Introduces AVANTRA Biomarker Workstation 82
Aureon Introduces Prostate Px® to Predict Progression and
Recurrence of Prostrate cancer 83
VisEn Introduces a Novel Imaging Agent 83
9. BIOMARKERS M&A ACTIVITY 84
QIAGEN to Take Over Stake in Alacris Theranostics 84
Transgenomic Acquires Certain Businesses of Clinical Data 84
Caliper Life Sciences Acquires Cambridge Research &
Instrumentation 84
Biosystems International and MicroBioChips Merge 85
Axela Takes Over Xceed Molecular 85
Accelrys Merges with Symyx Technologies 85
Caprion Proteomics Acquires PPDs Biomarker Division 86
QIAGEN Takes Over SABiosciences 86
Thermo Fisher Scientific Takes Over Brahms 86
QIAGEN Takes Over DxS 87
ICON Takes Over Veeda Laboratories 87
ID Business Solutions Takes Over InforSense 87
Clinical Data Acquires Avalon Pharmaceuticals 88
Genetix Takes Over SlidePath 88
Oxford Gene Technology Takes Over Sense Proteomic 88
Tethys Bioscience Takes Over Lipomics Technologies 88
QPS LLC Acquires Bio-Kinetic Clinical Applications 89
AltheaDx Rolls Out Affymetrix DMET Genotyping Microarray Service 89
10. COLLABORATIONS AND AGREEMENTS 90
Proteome Sciences Bags Contract from Eisai 90
MDxHealth to Ink Partnership Agreement with Pfizer, Cancer
Research Technology and Newcastle University 90
Takeda and Zinfandel Enter into License Agreement for AD
Biomarker 90
Pacific Biomarkers Forges Research Deals with Two
Multinational Firms 90
SMA Foundation and RBM Partner to Develop Panel of SMA Biomarker 91
Epigenomics Enters into Collaboration with QIAGEN to Develop
Colorectal Cancer Blood Tests 91
Vermillion Inks Agreement with Quest to Launch OVA1® in India 91
DiaGenic and Pfizer Team Up for Identifying Biomarkers for AD 92
Prometheus Signs Agreement with The Regents of the University
of California 92
Aushon BioSystems Enters into Partnership with LightArray Biotech 92
GE Healthcare Collaborates with Johnson & Johnson 93
ICON Enters into Strategic Alliance with Proteome Sciences 93
Epigenomics Inks Distribution Agreement with DATEKS 93
Epigenomics Inks Distribution Agreement with Pronto Diagnostics 93
Thermo Fisher Collaborates with Proteome Sciences 94
Diaceutics Teams Up with London Genetics to Develop Software
Decision Tools 94
OncoMethylome Enters Into Agreement with GlaxoSmithKline
Biologicals 94
SureGene Enters into Research Collaboration with Medco
Research Institute 95
Ariadne Inks Agreement with Roswell Park Cancer Institute and
Cellecta 95
SDIX Enters into Multi-Year Collaboration with Banyan Biomarkers 96
Roche Acquires Co-exclusive License from QIAGEN 96
Metabolon Collaborates with Colgate-Palmolive for Periodontal
Disease Biomarkers Identification 96
Toscana Biomarkers and Regione Toscana Enter into Grant Agreement 96
ACC and Roche Diagnostics Initiate Collaboration 97
Epigenomics Inks Distribution Agreement with DPC LEBANON 97
Duke Enters into Joint Venture with LabCorp for Biomarker
Commercialization 97
HDC and SPM Enter Into Agreement with Quest Diagnostics 98
Toscana Biomarkers Collaborates with QuantiScientifics 98
Intrinsic Bioprobes Licenses New Biomarkers to Ortho-Clinical
Diagnostics 98
Shimadzu Allies with Nonlinear Dynamics and Ceres Nanosciences 99
PAREXEL Enters into Partnership with Proteome Sciences 99
Biocartis Inks Agreement with Royal Philips Electronics 99
QIAGEN Signs Agreement with Wuxi AppTec 100
SDIX Enters into Collaboration with Fred Hutchinson Cancer
Research Center 100
Siemens Teams UP with EDPL to Institute Cyclotron Facility in
India 100
ALS TDI Concluded First Phase of Collaboration with Applied
Proteomics 101
Psynova Neurotech Teams Up with Roche for Schizophrenia
Treatment Development 101
Minerva Biotechnologies Licenses Exclusive Marketing Rights to
Clarient 102
Rules-Based Medicine Signs Biomarker-Driven Agreement with
Covance 102
BG Medicine and Abbott Ink Agreement for galectin-3 Biomarker 102
Epigenomics and ARUP Ink Non-Exclusive Agreement 102
Biosystems International Signs Licensing Agreement with
Lohocla Research 102
Axela Signs Agreements with Micromedics and Proteome Sciences 103
Moffitt Cancer Center and Frantz BioMarkers Enter into
Licensing Agreement 103
Fujirebio Diagnostics Signs Agreement with BD for Oncology
Diagnostic Assays 104
Quest Diagnostics Bags Prostrate Cancer Test License from
Epigenomics 104
Genedata Extends Collaboration Agreement with Roche 104
BioTheranostics Inks Commercialization Agreement with Lab 21
for THEROS CancerTYPE ID 104
Researchers Utilizes AB Sciex Qtrap 5500 System to Detect
Biomarkers 105
Fujirebio Inks Agreement with Abbott to Develop Ovarian Cancer
Test 105
Caprion and Applied Bioystems Partners to Accelerate
Validation and Verification of Protein Biomarker 105
Sysmex Inks Research Partnership Deal with Epigenomics 106
Pharsight Inks Agreement with InforSense 106
AstraZeneca and Washington University Team Up to Develop Novel
Methods for Alzheimers Disease Diagnosis and Treatment 106
11. OTHER CORPORATE INITIATIVES IN BIOMARKERS SPACE 107
Genedata Installs Genedata Expressionist® Refiner MS at
Victoria DPI 107
Genedata Deploys Genedata Expressionist® at Hospital for Sick
Children 107
Covance Establishes New Unit for Discovery and Translation
Services 107
The University of Liège Spins-off Targetome Business 107
PMDA Accepts Biomarker Panel of Critical Path's 107
Clarient Obtains UK Patents for the TLE3 Biomarker 108
Agilent Supplies Mass Spectrometry Devices to Stemina
Biomarker Discovery 108
Pacific Biomarkers to Launch New Logo, Marketing and Branding
Initiatives 108
SMA Foundation Completes Biomarker Study 108
Genedata Offers Genedata Expressionist® to RIKEN 109
Chronix Biomedical Strengthens Biomarker Development Capabilities 109
Aureon Changes Name of Colorectal Cancer Prognostic Test 109
Satoris Gains Global Distribution Rights to RBM's
DiscoveryMAP™ Panel 109
Teva Pharmaceutical Industries to Use Biomarkers of Compugen 110
Genedata Provides Genedata Expressionist® System to Asubio Pharma 110
InforSense Aids Biomarker Discovery Process by Celera 110
Xennex Provides Satoris with Access to GeneCards® 111
IME Developed Silicon-Based Testing System for Cardiac Biomarkers 111
12. FOCUS ON SELECT GLOBAL PLAYERS 112
Abbott Laboratories (US) 112
Affymetrix, Inc. (US) 112
Agilent Technologies, Inc. (US) 113
Alexion Pharmaceuticals, Inc. (USA) 113
Beckman Coulter, Inc. (US) 114
Becton, Dickinson and Company (US) 114
Bio-Rad Laboratories, Inc. (US) 115
BioMérieux (France) 115
Bruker Corporation (US) 115
Caprion Proteomics, Inc. (Canada) 116
Clarient Inc. (US) 117
Compugen, Ltd. (Israel) 117
Correlogic Systems, Inc. (US) 117
DiagnoCure, Inc. (Canada) 117
Epigenomics AG (Germany) 118
GE Healthcare (UK) 118
Gene Logic (US) 119
Genedata AG (Switzerland) 119
Gen-Probe Inc. (US) 119
GlaxoSmithKline Plc. (UK) 120
Hitachi Medical Corporation (Japan) 120
Illumina, Inc. (US) 121
LabCorp. (US) 121
Life Technologies Corporation (US) 122
Merck & Co., Inc. (US) 122
Metabolon, Inc. (US) 122
Myriad Genetics, Inc. (US) 123
Novartis International AG (Switzerland) 123
Panacea Laboratories (US) 124
Pfizer, Inc. (US) 124
Philips Healthcare (Netherlands) 125
QIAGEN NV (The Netherlands) 125
Quest Diagnostic, Inc. (US) 125
Roche Diagnostics Corp. (US) 126
Rubicon Genomics, Inc. (US) 126
Rules-Based Medicine, Inc. (US) 126
Siemens Healthcare Diagnostics, Inc. (US) 127
13. GLOBAL MARKET PERSPECTIVE 128
Table 14: World Recent Past, Current and Future Analysis for
Biomarkers by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2008
through 2017 (includes corresponding Graph/Chart) 128
Table 15: World 10-Year Perspective for Biomarkers by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 129
Table 16: World Recent Past, Current and Future Analysis for
Biomarker Technologies by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 130
Table 17: World 10-Year Perspective for Biomarker Technologies
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 131
Table 18: World Recent Past, Current and Future Analysis for
Biomarker Technologies by Segment - Emerging Biomarker
Technologies, Conventional Biomarker Technologies, and Other
Biomarker Technologies Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 132
Table 19: World 10-Year Perspective for Biomarker Technologies
by Segment - Percentage Breakdown of Dollar Sales for Emerging
Biomarker Technologies, Conventional Biomarker Technologies,
and Other Biomarker Technologies Markets for Years 2008, 2011
and 2017 (includes corresponding Graph/Chart) 132
Table 20: World Recent Past, Current and Future Analysis for
Emerging Biomarker Technologies by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 133
Table 21: World 10-Year Perspective for Emerging Biomarker
Technologies by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and
Rest of World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 134
Table 22: World Recent Past, Current and Future Analysis for
Emerging Biomarker Technologies by Segment - Imaging
biomarkers, Proteomics, Transcriptomics, and Bioinformatics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 135
Table 23: World 10-Year Perspective for Emerging Biomarker
Technologies by Segment - Percentage Breakdown of Dollar Sales
for Imaging biomarkers, Proteomics, Transcriptomics, and
Bioinformatics Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 135
Table 24: World Recent Past, Current and Future Analysis for
Imaging Biomarkers by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 136
Table 25: World 10-Year Perspective for Imaging Biomarkers by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 137
Table 26: World Recent Past, Current and Future Analysis for
Proteomics in Biomarkers Market by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 138
Table 27: World 10-Year Perspective for Proteomics in
Biomarker Market by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for Years 2008, 2011 and 2017
(includes corresponding Graph/Chart) 139
Table 28: World Recent Past, Current and Future Analysis for
Transcriptomics in Biomarkers Market by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 140
Table 29: World 10-Year Perspective for Transcriptomics in
Biomarkers Market by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for Years 2008, 2011 and 2017
(includes corresponding Graph/Chart) 141
Table 30: World Recent Past, Current and Future Analysis for
Bioinformatics in Biomarkers Market by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 142
Table 31: World 10-Year Perspective for Bioinformatics in
Biomarkers Market by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for Years 2008, 2011 and 2017
(includes corresponding Graph/Chart) 143
Table 32: World Recent Past, Current and Future Analysis for
Conventional Biomarker Technologies by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 144
Table 33: World 10-Year Perspective for Conventional Biomarker
Technologies by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and
Rest of World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 145
Table 34: World Recent Past, Current and Future Analysis for
Conventional Biomarker Technologies by Segment -
Immunodiagnostics and Molecular Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 146
Table 35: World 10-Year Perspective for Conventional Biomarker
Technologies by Segment - Percentage Breakdown of Dollar Sales
for Immunodiagnostics and Molecular Diagnostics Markets for
Years 2008, 2011, and 2017 (includes corresponding
Graph/Chart) 146
Table 36: World Recent Past, Current and Future Analysis for
Immunodiagnostics by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 147
Table 37: World 10-Year Perspective for Immunodiagnostics by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 148
Table 38: World Recent Past, Current and Future Analysis for
Molecular Diagnostics by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 149
Table 39: World 10-Year Perspective for Molecular Diagnostics
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 150
Table 40: World Recent Past, Current and Future Analysis for
Other Biomarker Technologies by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 151
Table 41: World 10-Year Perspective for Other Biomarker
Technologie by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and
Rest of World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 152
Table 42: World Recent Past, Current and Future Analysis for
Biomarker Services by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 153
Table 43: World 10-Year Perspective for Biomarker Services by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 154
Table 44: World Recent Past, Current and Future Analysis for
Biomarker Services by Segment- Clinical Biomarker Services,
Specimen Preparation, and Other Biomarker Services Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 155
Table 45: World 10-Year Perspective for Biomarker Services by
Segment - Percentage Breakdown of Dollar Sales for Clinical
Biomarker Services, Specimen Preparation, and Other Biomarker
Services Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 155
Table 46: World Recent Past, Current and Future Analysis for
Clinical Biomarker Services by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 156
Table 47: World 10-Year Perspective for Clinical Biomarker
Services by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of
World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 157
Table 48: World Recent Past, Current and Future Analysis for
Specimen Preparation by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 158
Table 49: World 10-Year Perspective for Specimen Preparation
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 159
Table 50: World Recent Past, Current and Future Analysis for
Other Biomarker Services by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 160
Table 51: World 10-Year Perspective for Other Biomarker
Services by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of
World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 161
Table 52: World Recent Past, Current and Future Analysis for
Biomarkers by Application - Biomarker Discovery, Clinical Drug
Development, and Diagnostics Techniques (Molecular) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 162
Table 53: World 10-Year Perspective for Biomarkers by
Application - Percentage Breakdown of Dollar Sales for
Biomarker Discovery, Clinical Drug Development, and
Diagnostics Techniques (Molecular) Markets for Years 2008,
2011 and 2017 (includes corresponding Graph/Chart) 162
Table 54: World Recent Past, Current and Future Analysis for
Biomarkers by Therapeutic Area - Cancer Biomarkers, Cardiology
Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 163
Table 55: World 10-Year Perspective for Biomarkers by
Therapeutic Area - Percentage Breakdown of Dollar Sales for
Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and
Other Therapeutic Biomarker Markets for Years 2008, 2011 and
2017 (includes corresponding Graph/Chart) 164
14. THE UNITED STATES 165
A.Market Analysis 165
Current & Future Analysis 165
Companies Wake Up to the Growing Need for Effective Biomarkers 165
Biomarker Regulations in the US 166
Product Launches 166
Strategic Corporate Developments 176
Focus on Select Major Players 189
B.Market Analytics 201
Table 56: The US Recent Past, Current and Future Analysis
for Biomarkers by Segment-Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 201
Table 57: The US 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 203
15. CANADA 204
A.Market Analysis 204
Current & Future Analysis 204
Product Launch 204
Strategic Corporate Developments 204
Focus on Select Major Players 206
B.Market Analytics 207
Table 58: Canadian Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 207
Table 59: Canadian 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 209
16. JAPAN 210
A.Market Analysis 210
Current & Future Analysis 210
Strategic Corporate Developments 210
Hitachi Medical Corporation - A Key Player 211
B.Market Analytics 212
Table 60: Japanese Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 212
Table 61: Japanese 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 214
17. EUROPE 215
A.Market Analysis 215
Current & Future Analysis 215
Biopharmaceutical Industry Tunes into Biomarker- Based Drug R&D 215
Biomarker Regulations in Europe 215
EMEA's Experience in Pharmacogenetic Drugs - Still Nascent 216
Uncertain Laws Discourage VC Funding in Europe 216
Uncertainty Continues Among Regulators over Biomarker
Validation Levels 216
B.Market Analytics 217
Table 62: European Recent Past, Current and Future Analysis
for Biomarkers by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2008
through 2017 (includes corresponding Graph/Chart) 217
Table 63: European 10-Year Perspective for Biomarkers by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK and Rest of Europe Markets for
Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 218
Table 64: European Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 219
Table 65: European 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 221
17a. FRANCE 222
A.Market Analysis 222
Current & Future Analysis 222
Strategic Corporate Development 222
BioMérieux (France) - A Key Player 222
B.Market Analytics 223
Table 66: French Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 223
Table 67: French 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 225
17b. GERMANY 226
A.Market Analysis 226
Current & Future Analysis 226
Product Launches 226
Strategic Corporate Development 227
Epigenomics AG - A Key Player 227
B.Market Analytics 228
Table 68: German Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 228
Table 69: German 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 230
17c. ITALY 231
A.Market Analysis 231
Current & Future Analysis 231
Strategic Corporate Developments 231
B.Market Analytics 232
Table 70: Italian Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 232
Table 71: Italian 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 234
17d. THE UNITED KINGDOM 235
A.Market Analysis 235
Current & Future Analysis 235
Product Launches 235
Strategic Corporate Developments 237
Focus on Select Major Players 241
B.Market Analytics 243
Table 72: The UK Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 243
Table 73: The UK 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 245
17e. REST OF EUROPE 246
A.Market Analysis 246
Current & Future Analysis 246
Product Launches 246
Strategic Corporate Developments 248
Focus on Select Major Players 251
B.Market Analytics 253
Table 74: Rest of European Recent Past, Current and Future
Analysis for Biomarkers by Segment- Biomarker Technologies
[Emerging Biomarker Technologies (Imaging Biomarkers,
Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 253
Table 75: Rest of European 10-Year Perspective for
Biomarkers by Segment - Percentage Breakdown of Dollar Sales
for Biomarker Technologies [Emerging Biomarker Technologies
(Imaging Biomarkers, Proteomics, Transcriptomics and
Bioinformatics), Conventional Biomarker Technologies
(Immunodiagnostics and Molecular Diagnostics) and Others]
and Biomarker Services [Clinical Biomarker Services,
Specimen Preparation and Others] Markets for Years 2008,
2011 and 2017 (includes corresponding Graph/Chart) 255
18. ASIA-PACIFIC 256
A.Market Analysis 256
Current & Future Analysis 256
Product Launches 256
Strategic Corporate Developments 257
B.Market Analytics 259
Table 76: Asia-Pacific Recent Past, Current and Future
Analysis for Biomarkers by Segment- Biomarker Technologies
[Emerging Biomarker Technologies (Imaging Biomarkers,
Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 259
Table 77: Asia-Pacific 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Servicesz
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 261
19. REST OF WORLD 262
A.Market Analysis 262
Strategic Corporate Development 262
Compugen Ltd. (Israel)- A Key Player 262
B.Market Analytics 263
Table 78: Rest of World Recent Past, Current and Future
Analysis for Biomarkers by Segment- Biomarker Technologies
[Emerging Biomarker Technologies Imaging Biomarkers,
Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 263
Table 79: Rest of World 10-Year Perspective for Biomarkers
by Segment - Percentage Breakdown of Dollar Sales for
Biomarker Technologies [Emerging Biomarker Technologies
(Imaging Biomarkers, Proteomics, Transcriptomics and
Bioinformatics), Conventional Biomarker Technologies
(Immunodiagnostics and Molecular Diagnostics) and Others]
and Biomarker Services [Clinical Biomarker Services,
Specimen Preparation and Others] Markets for Years 2008,
2011 and 2017 (includes corresponding Graph/Chart) 265
COMPETITIVE LANDSCAPE
Total Companies Profiled: 204 (including Divisions/Subsidiaries - 210)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 132
Canada 10
Japan 3
Europe 56
France 9
Germany 7
The United Kingdom 17
Italy 1
Rest of Europe 22
Asia-Pacific (Excluding Japan) 4
Middle-East 5
------------------------------------------
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 2
Quantitative Techniques & Analytics 3
Product Definition and Scope of Study 3
Definitions 4
Biomarker Technologies 4
Emerging Biomarker Technologies 4
Proteomics 4
Transcriptomics 5
Imaging biomarkers 5
Bioinformatics 5
Conventional Biomarker Technologies 5
Molecular Diagnostics 5
Immunodiagnostics 6
Other Biomarker Technologies 6
Metabolite and Enzyme Assays 6
Reagents 6
Biomarker Services 6
Clinical Biomarker Services 6
Biomarker Testing 6
Assay Development and Production 6
Antibody Development 7
Specimen Preparation 7
Bioinformatics and Others 7
2. INDUSTRY OVERVIEW 8
Global Biomarkers Market Surges in the Backdrop of Widening
Medical Scope and Applications 8
Factors Engendering Positive Vibes 8
Factors Engendering Positive Influence on the Biomarkers
Market: A Summary 9
Biomarkers: A Regional Perspective 9
US Spearheads the Global Biomarkers Market 9
US and Japan Take Lead on the Patent Front 10
Table 1: Dominance of US in the Global Biomarker Patent
Filings (includes corresponding Graph/Chart) 10
Table 2: Leading Players in the Biomarkers Space by Number
of Patent Filings (includes corresponding Graph/Chart) 11
Table 3: Number of Biomarker Patents Published and Filed:
2003-2007 (includes corresponding Graph/Chart) 11
Asia-Pacific: The Fastest Growing Biomarker Market 12
Supportive Governments and Regulatory Bodies to Fuel Growth 12
Increasing Collaborations Among Regulators and Companies
Augur Well for Biomarkers 12
Player Strategies: An Insight 13
Table 4: Growing Number of Biomarker Deals (includes
corresponding Graph/Chart) 13
Table 5: Competitive Strategy Mix in the Global Oncology
Biomarkers Market (includes corresponding Graph/Chart) 14
Pharma and Biomarker Developer Tie-Ups to Raise Drug
Development Productivity 14
3. MARKET OUTLOOK 15
Biomarkers: Evolving Scope and Applications 15
Technological Advancements - A Boon for Biomarker Discovery 15
Evolving Role of Biomarkers in Drug Development 16
Companion Biomarkers 16
Biomarkers Play Invaluable Role in Oncology and Cardiovascular
Disease Diagnosis 16
Personalized Medicine- Revolutionizing the Medical Treatment 17
Biomarker-Led Drug Discovery - A Profitable Investment 18
Technological Trends 18
Proteins Gain Upper Hand in Biomarkers 18
Mass Spectrometry - A Promising Technology in Molecular Medicine 18
Market Restraints 19
Challenges in Biomarker Validation - A Major Growth Retardant 19
The Road Ahead 19
Biomarkers to Witness Significant Growth in Therapeutic and
Diagnostic Arenas 19
Efficiency Improvements Must for Realizing Cost-Effective
Biomarker Testing 20
4. BIOMARKER TECHNOLOGIES AND SERVICES: AN OVERVIEW 21
Biomarker - Definition & Introduction 21
BIOMARKER TECHNOLOGIES 21
EMERGING BIOMARKER TECHNOLOGIES 21
Proteomics 22
Growth Drivers and Market Trends 22
Efficiency Gains in Drug Discovery Drive Growth in Proteomics 22
Proteomics Witness Increased Focus on Targeted Approach 22
Mass Spectrometry -Shifts in Focus to Proteomics Helps
Biomarker Development 23
Mass Spectrometry Expands Scope of Protein Biomarker
Applications 23
Transcriptomics 23
Transcriptomics - Assisting in Identification of Biomarkers 23
Imaging Biomarkers: Disease Diagnosis, the Non-Invasive way 24
Types of Imaging Biomarkers - An Overview 24
Market Trends 25
Molecular Imaging - Gaining Importance in Drug Discovery
and Development 25
Use of Molecular Imaging in Clinical Trials for Drug
Development 25
Bioinformatics 26
CONVENTIONAL BIOMARKER TECHNOLOGIES 26
Molecular Diagnostics 26
Immunodiagnostics 26
Market Trends 26
Growth in Use of Molecular Diagnostics to Propel Biomarker
Growth 26
Demand for Novel Biomarkers Persists in Immunodiagnostics 27
Immunoassays Plagued with Standardization Issues 27
OTHER BIOMARKER TECHNOLOGIES 27
Metabolite and Enzyme Assays 27
Reagents 28
Market Trends 28
Microarrays Surge Biomarker Identification 28
Metabolomics Gain Rapid Foothold in Drug Discovery 28
BIOMARKER SERVICES 28
Expanding Capabilities Drive Large-Scale Adoption 29
Clinical Biomarker Services 29
Biomarker Testing 29
Assay Development and Production 30
Antibody Development 30
Specimen Preparation 30
Bioinformatics and Other Biomarker Services 31
Bioinformatics Gain Prominence 31
miRNA Analysis 31
Microarray Services Witness Increasing Investments 31
5. BIOMARKERS MARKET BY APPLICATION 32
Role of Biomarkers in Drug Discovery and Development 32
Role of Biomarkers in Clinical Research and Patient Management 32
Major Benefits of Biomarkers in Clinical Development 33
Major Benefits of Biomarkers in Medicine 33
Multifarious Applications of Biomarkers 33
New Applications Come to the Fore 33
Application of Biomarkers in Drug Development 34
Herceptin and Vilazodone -References for Success of Biomarker
Based Approach 34
Increasing Role of Biomarkers in Modern Drug R&D 35
Translational Medicine Biomarkers Revolutionizing Drug
Development Process 35
Outsourcing - Opportunities Galore 35
CROs in a Dilemma Over Investments in Biomarker Analysis
Services 36
Lower Productivity of Traditional Drug Discovery Approach
Calls for New Methods 36
Blockbuster Model Versus Personalized Medication Model 37
Workflow Standardization - Key to Success of Biomarkers in
Drug Development 37
6. BIOMARKERS BY THERAPEUTIC AREA 38
Current & Future Analysis 38
ONCOLOGY 38
Factors Driving Oncology Biomarkers' Growth 38
US Remains at the Forefront of Cancer Biomarker Patent Filings 39
Table 6: Regional Split in the Global Cancer Biomarker
Patent Filings: 2009 (includes corresponding Graph/Chart) 39
Table 7: Leading Players in Cancer Biomarkers by Number of
Patent Filings: 2004-2009 39
Global Oncology Diagnostics and Drug Discovery Biomarkers Market 40
Table 8: World Recent Past, Current and Future Analysis for
Oncology Biomarkers Market by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 41
Table 9: World 10-Year Perspective for Oncology Biomarkers
Market by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest
of World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 42
Table 10: Global Cancer Biomarkers Diagnostics (Molecular)
Market by Company (2009): Market Share Breakdown of Revenues
for Roche, Gen-Probe, Myriad, Abbott, QIAGEN and Others
(includes corresponding Graph/Chart) 43
Evolution of Oncology Biomarkers 43
Available and Pipeline Biomarkers in Various Cancers 44
Breast Cancer Dominates Cancer Biomarkers Pipeline 44
Table 11: Global Cancer Biomarkers Pipeline by Indication
(2010): Percentage Share Breakdown for Breast Cancer,
Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and
Others (includes corresponding Graph/Chart) 45
Table 12: Global Oncology Biomarkers Market: Percentage
Breakdown of Patent Filings by Oncology Area (2007) 45
Breast Cancer Market Awaits New Specific Biomarkers 45
Oncology Biomarker Diagnostic Techniques 46
Table 13: Leading Cancer Biomarker Diagnostic Technologies
(2009): Percentage Share of Value Sales for Gene-based
Markers, Proteomics, DNA Microarrays, Immunological Markers
and IHC Tests, and Others (includes corresponding
Graph/Chart) 46
Current Trends in Cancer Biomarkers 47
Validation Techniques Take Center Stage 47
Early-Stage Use of Biomarkers High in Oncology 47
Proteomics Ahead of Genomic Biomarkers in Functionality 48
Pharmacogenomics and IHC Tests Inch Ahead in Cancer
Biomarker Diagnostics 48
Faster Diagnosis Benefits DNA Microarray Technology 48
Other Tests Lose Market Share 49
Companion Biomarkers in Oncology 49
CARDIOLOGY 49
Market Trends 50
Increasing Health Burden Drives Research Efforts 50
Gene Expression Analysis Delivers Novel Therapeutic Approaches 50
High-Performance Techniques Drive Biomarker Discovery in
Cardiology 51
Effective Phenotyping Takes Precedence for Successful
Genotyping Studies 51
Role of Linkage Analysis in Cardiovascular Biomarker
Identification 51
Biomarkers of ACS 51
Biomarkers - A Promising Diagnostic Tool for ACS 52
Biomarker Discovery in Cardiovascular Diseases to Undergo
Significant Changes 52
Major Cardiovascular Diagnostic Biomarkers - A Focus on
Biomarkers for ACS 53
Creatine Kinase-Myocardial Band 53
Natriuretic Peptides 53
Cardiac Troponin 53
Myoglobin 53
New Diagnostic Biomarkers for ACS on the Anvil 54
Genomic Biomarkers for Detecting Cardiovascular Diseases 54
Growing Demand for Stroke Biomarkers 55
Rising Incidence of the Disease - A Major Driver for Stroke
Biomarkers 55
CENTRAL NERVOUS SYSTEM (CNS) 55
Lower Commercial Availability Restricts Market Share 56
Research Efforts Remain Confined to Specific Areas 56
High Cost of Treatment Shadows Biomarkers' Short-Treatment
Benefits 56
Research Methodology in CNS Biomarkers 56
Alliances - A Key Aspect to the Development of CNS Biomarkers 57
Biomarkers in Select CNS Diseases 57
Alzheimers Disease 57
Parkinsons Disease Biomarkers - Crucial for
Neuroprotectants' Effectiveness 58
Schizophrenia: An Unexploited Segment 58
OTHER THERAPEUTIC AREAS 58
Inflammatory and Autoimmune Disorders 58
Biomarkers offer Efficient Diagnosis and Treatment 59
Rheumatology 59
7. AN OVERVIEW OF SELECT BIOMARKERS 60
HER2/neu/ ErbB2 Gene 60
HER2 and its Association with Cancer 60
Target Drugs for HER2 60
Hepsin Biomarkers 60
Early Prostate Cancer Antigen-2 60
MMP-3 61
ImmunoCyt™/uCyt+™ 61
AmpliChip CYP450 Test 62
The OncoVue® Breast Cancer Risk Test 62
Oncotype DX® Test 62
Oncotype DX Colon Cancer Assay 63
MammaPrint 63
Theros CancerTYPE ID 63
PgxPredict:CLOZAPINE- Test for Qualifying Patients to Use
Clozapine 63
The Pathwork Tissue of Origin Test 64
PROGENSA PCA3 Assay 64
Epi proColon® Early Detection Assay 64
OVA1® Test 65
Bcr-abl Fusion Protein 65
HLA-B 65
Mammostrat® 65
Ipsogen MapQuant Dx™ Genomic Grade 66
CA1-18 Enzyme Immunoassay (EIA) 66
Anti-L523S Antibody 66
8. PRODUCT INTRODUCTIONS IN THE BIOMARKERS SPACE 67
RBM Unveils OncologyMAP® Panel of 101 Quantitative Biomarker
Tests 67
Avantra Introduces New BioChip Immunoassay Biomarker Workstation 67
Clarient Introduces Mammostrat Test 67
Biomagnetics Diagnostics Identifies Second Biomarker for
Tuberculosis Assay 68
Epistem Introduces Novel Ex Vivo Plucked Hair Biomarker Assay 68
Crescendo Bioscience Launches New Multi Biomarker Blood Test 68
Alere International Launches New Triage® NT-proBNP Test 68
Agilent Technologies Launches New SureSelect Kinome Target
Enrichment Kit 69
Roche Diagnostics to Launch New STAT Immunoassays 69
Gentel Biosciences Launches New Human Profiling Kits 69
QIAGEN Introduces QIAsymphony RGQ System 70
Almac Introduces Biomarkers for Biopharmaceutical Industry 70
i-Path Introduces TMA Toolbox 71
Abbott Introduces ARCHITECTPLUS Systems 71
Affymetrix Introduces QuantiGene® ViewRNA Assayformats 72
ARUP Laboratories Introduces New Test for Colorectal Caner
Detection 72
Warnex Launches Blood Testing Service for Colorectal Cancer in
Canada 72
Agilent Technologies Launches mAb-Glyco-Chip 73
synlab Launches Septin9 Testing in Germany 73
IDBS Introduces New Biomarker Discovery and Validation Solution 73
Quest Diagnostics Introduces Blood Test for Detecting
Colorectal Cancer 74
Clarient Introduces Biomarker Panel for NSCLC Classification 74
Institute of Microelectronics and Agency for Science,
Technology and Research Launch Rapid Cardiac Biomarker Test 74
Rules-Based Medicine Unveils CardiovascularMAP™ for CVD Treatment 75
Thermo Fisher Introduces New Copeptin Assay 75
Psynova Neurotech and RBM Identify New Biomarkers for
Schizophrenia 75
Genedata Unveils Genedata Expressionist® 5.3 75
Arrayit Introduces Biomarker Discovery Service 76
Invitrogen Introduces Biomarker Tool for Kidney Function Research 76
Abbott Introduces ARCHITECT® c4000® 76
Epigenomics Rolls Out Epi proColon Range in Europe 77
Genedata Introduces Expressionist 5.2 for Identifying MS-based
Biomarker 77
VisEn Unveils FAST - A Novel Imaging Platform 77
Millipore and CXR Biosciences Unveils ToxReporter™ 78
Rules-Based Medicine Unveils Human Kidney Multi-Analyte Profile 78
MDS and Applied Biosystems Launch AB SCIEX TOF/TOF™ 5800 System 78
Genetic Biomarkers for Chronic Kidney Disease 79
Bruker Launches Advanced MALDI-TOF/TOF Mass Spectrometer 79
Satoris Introduces three Novel Blood Tests 79
GE Healthcare Launches Discovery™ MR450 79
GE Healthcare in Partnership with Varian Launches Discovery
MR901 (US) 80
Applied Biosystems and MDS Analytical Launches Novel New Mass
Spectrometry Tools 80
Rules-Based Medicine Commercializes Rat Kidney MAP Biomarker
Panel 80
Thomson Reuters Introduces BIOMARKERcenter 81
Gentel® Biosciences Introduces SilverQuant™ GlycoBiomarker
Array Kit 81
BioMarker Pharmaceuticals Introduces Gene Essence™ DNA Test 82
mtm laboratories Introduces Cervatec™ Assay 82
Decision Biomarkers Introduces AVANTRA Biomarker Workstation 82
Aureon Introduces Prostate Px® to Predict Progression and
Recurrence of Prostrate cancer 83
VisEn Introduces a Novel Imaging Agent 83
9. BIOMARKERS M&A ACTIVITY 84
QIAGEN to Take Over Stake in Alacris Theranostics 84
Transgenomic Acquires Certain Businesses of Clinical Data 84
Caliper Life Sciences Acquires Cambridge Research &
Instrumentation 84
Biosystems International and MicroBioChips Merge 85
Axela Takes Over Xceed Molecular 85
Accelrys Merges with Symyx Technologies 85
Caprion Proteomics Acquires PPDs Biomarker Division 86
QIAGEN Takes Over SABiosciences 86
Thermo Fisher Scientific Takes Over Brahms 86
QIAGEN Takes Over DxS 87
ICON Takes Over Veeda Laboratories 87
ID Business Solutions Takes Over InforSense 87
Clinical Data Acquires Avalon Pharmaceuticals 88
Genetix Takes Over SlidePath 88
Oxford Gene Technology Takes Over Sense Proteomic 88
Tethys Bioscience Takes Over Lipomics Technologies 88
QPS LLC Acquires Bio-Kinetic Clinical Applications 89
AltheaDx Rolls Out Affymetrix DMET Genotyping Microarray Service 89
10. COLLABORATIONS AND AGREEMENTS 90
Proteome Sciences Bags Contract from Eisai 90
MDxHealth to Ink Partnership Agreement with Pfizer, Cancer
Research Technology and Newcastle University 90
Takeda and Zinfandel Enter into License Agreement for AD
Biomarker 90
Pacific Biomarkers Forges Research Deals with Two
Multinational Firms 90
SMA Foundation and RBM Partner to Develop Panel of SMA Biomarker 91
Epigenomics Enters into Collaboration with QIAGEN to Develop
Colorectal Cancer Blood Tests 91
Vermillion Inks Agreement with Quest to Launch OVA1® in India 91
DiaGenic and Pfizer Team Up for Identifying Biomarkers for AD 92
Prometheus Signs Agreement with The Regents of the University
of California 92
Aushon BioSystems Enters into Partnership with LightArray Biotech 92
GE Healthcare Collaborates with Johnson & Johnson 93
ICON Enters into Strategic Alliance with Proteome Sciences 93
Epigenomics Inks Distribution Agreement with DATEKS 93
Epigenomics Inks Distribution Agreement with Pronto Diagnostics 93
Thermo Fisher Collaborates with Proteome Sciences 94
Diaceutics Teams Up with London Genetics to Develop Software
Decision Tools 94
OncoMethylome Enters Into Agreement with GlaxoSmithKline
Biologicals 94
SureGene Enters into Research Collaboration with Medco
Research Institute 95
Ariadne Inks Agreement with Roswell Park Cancer Institute and
Cellecta 95
SDIX Enters into Multi-Year Collaboration with Banyan Biomarkers 96
Roche Acquires Co-exclusive License from QIAGEN 96
Metabolon Collaborates with Colgate-Palmolive for Periodontal
Disease Biomarkers Identification 96
Toscana Biomarkers and Regione Toscana Enter into Grant Agreement 96
ACC and Roche Diagnostics Initiate Collaboration 97
Epigenomics Inks Distribution Agreement with DPC LEBANON 97
Duke Enters into Joint Venture with LabCorp for Biomarker
Commercialization 97
HDC and SPM Enter Into Agreement with Quest Diagnostics 98
Toscana Biomarkers Collaborates with QuantiScientifics 98
Intrinsic Bioprobes Licenses New Biomarkers to Ortho-Clinical
Diagnostics 98
Shimadzu Allies with Nonlinear Dynamics and Ceres Nanosciences 99
PAREXEL Enters into Partnership with Proteome Sciences 99
Biocartis Inks Agreement with Royal Philips Electronics 99
QIAGEN Signs Agreement with Wuxi AppTec 100
SDIX Enters into Collaboration with Fred Hutchinson Cancer
Research Center 100
Siemens Teams UP with EDPL to Institute Cyclotron Facility in
India 100
ALS TDI Concluded First Phase of Collaboration with Applied
Proteomics 101
Psynova Neurotech Teams Up with Roche for Schizophrenia
Treatment Development 101
Minerva Biotechnologies Licenses Exclusive Marketing Rights to
Clarient 102
Rules-Based Medicine Signs Biomarker-Driven Agreement with
Covance 102
BG Medicine and Abbott Ink Agreement for galectin-3 Biomarker 102
Epigenomics and ARUP Ink Non-Exclusive Agreement 102
Biosystems International Signs Licensing Agreement with
Lohocla Research 102
Axela Signs Agreements with Micromedics and Proteome Sciences 103
Moffitt Cancer Center and Frantz BioMarkers Enter into
Licensing Agreement 103
Fujirebio Diagnostics Signs Agreement with BD for Oncology
Diagnostic Assays 104
Quest Diagnostics Bags Prostrate Cancer Test License from
Epigenomics 104
Genedata Extends Collaboration Agreement with Roche 104
BioTheranostics Inks Commercialization Agreement with Lab 21
for THEROS CancerTYPE ID 104
Researchers Utilizes AB Sciex Qtrap 5500 System to Detect
Biomarkers 105
Fujirebio Inks Agreement with Abbott to Develop Ovarian Cancer
Test 105
Caprion and Applied Bioystems Partners to Accelerate
Validation and Verification of Protein Biomarker 105
Sysmex Inks Research Partnership Deal with Epigenomics 106
Pharsight Inks Agreement with InforSense 106
AstraZeneca and Washington University Team Up to Develop Novel
Methods for Alzheimers Disease Diagnosis and Treatment 106
11. OTHER CORPORATE INITIATIVES IN BIOMARKERS SPACE 107
Genedata Installs Genedata Expressionist® Refiner MS at
Victoria DPI 107
Genedata Deploys Genedata Expressionist® at Hospital for Sick
Children 107
Covance Establishes New Unit for Discovery and Translation
Services 107
The University of Liège Spins-off Targetome Business 107
PMDA Accepts Biomarker Panel of Critical Path's 107
Clarient Obtains UK Patents for the TLE3 Biomarker 108
Agilent Supplies Mass Spectrometry Devices to Stemina
Biomarker Discovery 108
Pacific Biomarkers to Launch New Logo, Marketing and Branding
Initiatives 108
SMA Foundation Completes Biomarker Study 108
Genedata Offers Genedata Expressionist® to RIKEN 109
Chronix Biomedical Strengthens Biomarker Development Capabilities 109
Aureon Changes Name of Colorectal Cancer Prognostic Test 109
Satoris Gains Global Distribution Rights to RBM's
DiscoveryMAP™ Panel 109
Teva Pharmaceutical Industries to Use Biomarkers of Compugen 110
Genedata Provides Genedata Expressionist® System to Asubio Pharma 110
InforSense Aids Biomarker Discovery Process by Celera 110
Xennex Provides Satoris with Access to GeneCards® 111
IME Developed Silicon-Based Testing System for Cardiac Biomarkers 111
12. FOCUS ON SELECT GLOBAL PLAYERS 112
Abbott Laboratories (US) 112
Affymetrix, Inc. (US) 112
Agilent Technologies, Inc. (US) 113
Alexion Pharmaceuticals, Inc. (USA) 113
Beckman Coulter, Inc. (US) 114
Becton, Dickinson and Company (US) 114
Bio-Rad Laboratories, Inc. (US) 115
BioMérieux (France) 115
Bruker Corporation (US) 115
Caprion Proteomics, Inc. (Canada) 116
Clarient Inc. (US) 117
Compugen, Ltd. (Israel) 117
Correlogic Systems, Inc. (US) 117
DiagnoCure, Inc. (Canada) 117
Epigenomics AG (Germany) 118
GE Healthcare (UK) 118
Gene Logic (US) 119
Genedata AG (Switzerland) 119
Gen-Probe Inc. (US) 119
GlaxoSmithKline Plc. (UK) 120
Hitachi Medical Corporation (Japan) 120
Illumina, Inc. (US) 121
LabCorp. (US) 121
Life Technologies Corporation (US) 122
Merck & Co., Inc. (US) 122
Metabolon, Inc. (US) 122
Myriad Genetics, Inc. (US) 123
Novartis International AG (Switzerland) 123
Panacea Laboratories (US) 124
Pfizer, Inc. (US) 124
Philips Healthcare (Netherlands) 125
QIAGEN NV (The Netherlands) 125
Quest Diagnostic, Inc. (US) 125
Roche Diagnostics Corp. (US) 126
Rubicon Genomics, Inc. (US) 126
Rules-Based Medicine, Inc. (US) 126
Siemens Healthcare Diagnostics, Inc. (US) 127
13. GLOBAL MARKET PERSPECTIVE 128
Table 14: World Recent Past, Current and Future Analysis for
Biomarkers by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2008
through 2017 (includes corresponding Graph/Chart) 128
Table 15: World 10-Year Perspective for Biomarkers by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 129
Table 16: World Recent Past, Current and Future Analysis for
Biomarker Technologies by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 130
Table 17: World 10-Year Perspective for Biomarker Technologies
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 131
Table 18: World Recent Past, Current and Future Analysis for
Biomarker Technologies by Segment - Emerging Biomarker
Technologies, Conventional Biomarker Technologies, and Other
Biomarker Technologies Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 132
Table 19: World 10-Year Perspective for Biomarker Technologies
by Segment - Percentage Breakdown of Dollar Sales for Emerging
Biomarker Technologies, Conventional Biomarker Technologies,
and Other Biomarker Technologies Markets for Years 2008, 2011
and 2017 (includes corresponding Graph/Chart) 132
Table 20: World Recent Past, Current and Future Analysis for
Emerging Biomarker Technologies by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 133
Table 21: World 10-Year Perspective for Emerging Biomarker
Technologies by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and
Rest of World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 134
Table 22: World Recent Past, Current and Future Analysis for
Emerging Biomarker Technologies by Segment - Imaging
biomarkers, Proteomics, Transcriptomics, and Bioinformatics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 135
Table 23: World 10-Year Perspective for Emerging Biomarker
Technologies by Segment - Percentage Breakdown of Dollar Sales
for Imaging biomarkers, Proteomics, Transcriptomics, and
Bioinformatics Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 135
Table 24: World Recent Past, Current and Future Analysis for
Imaging Biomarkers by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 136
Table 25: World 10-Year Perspective for Imaging Biomarkers by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 137
Table 26: World Recent Past, Current and Future Analysis for
Proteomics in Biomarkers Market by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 138
Table 27: World 10-Year Perspective for Proteomics in
Biomarker Market by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for Years 2008, 2011 and 2017
(includes corresponding Graph/Chart) 139
Table 28: World Recent Past, Current and Future Analysis for
Transcriptomics in Biomarkers Market by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 140
Table 29: World 10-Year Perspective for Transcriptomics in
Biomarkers Market by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for Years 2008, 2011 and 2017
(includes corresponding Graph/Chart) 141
Table 30: World Recent Past, Current and Future Analysis for
Bioinformatics in Biomarkers Market by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 142
Table 31: World 10-Year Perspective for Bioinformatics in
Biomarkers Market by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for Years 2008, 2011 and 2017
(includes corresponding Graph/Chart) 143
Table 32: World Recent Past, Current and Future Analysis for
Conventional Biomarker Technologies by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 144
Table 33: World 10-Year Perspective for Conventional Biomarker
Technologies by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and
Rest of World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 145
Table 34: World Recent Past, Current and Future Analysis for
Conventional Biomarker Technologies by Segment -
Immunodiagnostics and Molecular Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 146
Table 35: World 10-Year Perspective for Conventional Biomarker
Technologies by Segment - Percentage Breakdown of Dollar Sales
for Immunodiagnostics and Molecular Diagnostics Markets for
Years 2008, 2011, and 2017 (includes corresponding
Graph/Chart) 146
Table 36: World Recent Past, Current and Future Analysis for
Immunodiagnostics by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 147
Table 37: World 10-Year Perspective for Immunodiagnostics by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 148
Table 38: World Recent Past, Current and Future Analysis for
Molecular Diagnostics by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 149
Table 39: World 10-Year Perspective for Molecular Diagnostics
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 150
Table 40: World Recent Past, Current and Future Analysis for
Other Biomarker Technologies by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 151
Table 41: World 10-Year Perspective for Other Biomarker
Technologie by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and
Rest of World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 152
Table 42: World Recent Past, Current and Future Analysis for
Biomarker Services by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 153
Table 43: World 10-Year Perspective for Biomarker Services by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 154
Table 44: World Recent Past, Current and Future Analysis for
Biomarker Services by Segment- Clinical Biomarker Services,
Specimen Preparation, and Other Biomarker Services Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 155
Table 45: World 10-Year Perspective for Biomarker Services by
Segment - Percentage Breakdown of Dollar Sales for Clinical
Biomarker Services, Specimen Preparation, and Other Biomarker
Services Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 155
Table 46: World Recent Past, Current and Future Analysis for
Clinical Biomarker Services by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 156
Table 47: World 10-Year Perspective for Clinical Biomarker
Services by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of
World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 157
Table 48: World Recent Past, Current and Future Analysis for
Specimen Preparation by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 158
Table 49: World 10-Year Perspective for Specimen Preparation
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 159
Table 50: World Recent Past, Current and Future Analysis for
Other Biomarker Services by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 160
Table 51: World 10-Year Perspective for Other Biomarker
Services by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of
World Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 161
Table 52: World Recent Past, Current and Future Analysis for
Biomarkers by Application - Biomarker Discovery, Clinical Drug
Development, and Diagnostics Techniques (Molecular) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 162
Table 53: World 10-Year Perspective for Biomarkers by
Application - Percentage Breakdown of Dollar Sales for
Biomarker Discovery, Clinical Drug Development, and
Diagnostics Techniques (Molecular) Markets for Years 2008,
2011 and 2017 (includes corresponding Graph/Chart) 162
Table 54: World Recent Past, Current and Future Analysis for
Biomarkers by Therapeutic Area - Cancer Biomarkers, Cardiology
Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 163
Table 55: World 10-Year Perspective for Biomarkers by
Therapeutic Area - Percentage Breakdown of Dollar Sales for
Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and
Other Therapeutic Biomarker Markets for Years 2008, 2011 and
2017 (includes corresponding Graph/Chart) 164
14. THE UNITED STATES 165
A.Market Analysis 165
Current & Future Analysis 165
Companies Wake Up to the Growing Need for Effective Biomarkers 165
Biomarker Regulations in the US 166
Product Launches 166
Strategic Corporate Developments 176
Focus on Select Major Players 189
B.Market Analytics 201
Table 56: The US Recent Past, Current and Future Analysis
for Biomarkers by Segment-Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 201
Table 57: The US 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 203
15. CANADA 204
A.Market Analysis 204
Current & Future Analysis 204
Product Launch 204
Strategic Corporate Developments 204
Focus on Select Major Players 206
B.Market Analytics 207
Table 58: Canadian Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 207
Table 59: Canadian 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 209
16. JAPAN 210
A.Market Analysis 210
Current & Future Analysis 210
Strategic Corporate Developments 210
Hitachi Medical Corporation - A Key Player 211
B.Market Analytics 212
Table 60: Japanese Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 212
Table 61: Japanese 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 214
17. EUROPE 215
A.Market Analysis 215
Current & Future Analysis 215
Biopharmaceutical Industry Tunes into Biomarker- Based Drug R&D 215
Biomarker Regulations in Europe 215
EMEA's Experience in Pharmacogenetic Drugs - Still Nascent 216
Uncertain Laws Discourage VC Funding in Europe 216
Uncertainty Continues Among Regulators over Biomarker
Validation Levels 216
B.Market Analytics 217
Table 62: European Recent Past, Current and Future Analysis
for Biomarkers by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2008
through 2017 (includes corresponding Graph/Chart) 217
Table 63: European 10-Year Perspective for Biomarkers by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK and Rest of Europe Markets for
Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 218
Table 64: European Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 219
Table 65: European 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 221
17a. FRANCE 222
A.Market Analysis 222
Current & Future Analysis 222
Strategic Corporate Development 222
BioMérieux (France) - A Key Player 222
B.Market Analytics 223
Table 66: French Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 223
Table 67: French 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 225
17b. GERMANY 226
A.Market Analysis 226
Current & Future Analysis 226
Product Launches 226
Strategic Corporate Development 227
Epigenomics AG - A Key Player 227
B.Market Analytics 228
Table 68: German Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 228
Table 69: German 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 230
17c. ITALY 231
A.Market Analysis 231
Current & Future Analysis 231
Strategic Corporate Developments 231
B.Market Analytics 232
Table 70: Italian Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 232
Table 71: Italian 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 234
17d. THE UNITED KINGDOM 235
A.Market Analysis 235
Current & Future Analysis 235
Product Launches 235
Strategic Corporate Developments 237
Focus on Select Major Players 241
B.Market Analytics 243
Table 72: The UK Recent Past, Current and Future Analysis
for Biomarkers by Segment- Biomarker Technologies [Emerging
Biomarker Technologies (Imaging Biomarkers, Proteomics,
Transcriptomics and Bioinformatics), Conventional Biomarker
Technologies (Immunodiagnostics and Molecular Diagnostics)
and Others] and Biomarker Services [Clinical Biomarker
Services, Specimen Preparation and Others] Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 243
Table 73: The UK 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 245
17e. REST OF EUROPE 246
A.Market Analysis 246
Current & Future Analysis 246
Product Launches 246
Strategic Corporate Developments 248
Focus on Select Major Players 251
B.Market Analytics 253
Table 74: Rest of European Recent Past, Current and Future
Analysis for Biomarkers by Segment- Biomarker Technologies
[Emerging Biomarker Technologies (Imaging Biomarkers,
Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 253
Table 75: Rest of European 10-Year Perspective for
Biomarkers by Segment - Percentage Breakdown of Dollar Sales
for Biomarker Technologies [Emerging Biomarker Technologies
(Imaging Biomarkers, Proteomics, Transcriptomics and
Bioinformatics), Conventional Biomarker Technologies
(Immunodiagnostics and Molecular Diagnostics) and Others]
and Biomarker Services [Clinical Biomarker Services,
Specimen Preparation and Others] Markets for Years 2008,
2011 and 2017 (includes corresponding Graph/Chart) 255
18. ASIA-PACIFIC 256
A.Market Analysis 256
Current & Future Analysis 256
Product Launches 256
Strategic Corporate Developments 257
B.Market Analytics 259
Table 76: Asia-Pacific Recent Past, Current and Future
Analysis for Biomarkers by Segment- Biomarker Technologies
[Emerging Biomarker Technologies (Imaging Biomarkers,
Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 259
Table 77: Asia-Pacific 10-Year Perspective for Biomarkers by
Segment - Percentage Breakdown of Dollar Sales for Biomarker
Technologies [Emerging Biomarker Technologies (Imaging
Biomarkers, Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Servicesz
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets for Years 2008, 2011 and 2017 (includes
corresponding Graph/Chart) 261
19. REST OF WORLD 262
A.Market Analysis 262
Strategic Corporate Development 262
Compugen Ltd. (Israel)- A Key Player 262
B.Market Analytics 263
Table 78: Rest of World Recent Past, Current and Future
Analysis for Biomarkers by Segment- Biomarker Technologies
[Emerging Biomarker Technologies Imaging Biomarkers,
Proteomics, Transcriptomics and Bioinformatics),
Conventional Biomarker Technologies (Immunodiagnostics and
Molecular Diagnostics) and Others] and Biomarker Services
[Clinical Biomarker Services, Specimen Preparation and
Others] Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 263
Table 79: Rest of World 10-Year Perspective for Biomarkers
by Segment - Percentage Breakdown of Dollar Sales for
Biomarker Technologies [Emerging Biomarker Technologies
(Imaging Biomarkers, Proteomics, Transcriptomics and
Bioinformatics), Conventional Biomarker Technologies
(Immunodiagnostics and Molecular Diagnostics) and Others]
and Biomarker Services [Clinical Biomarker Services,
Specimen Preparation and Others] Markets for Years 2008,
2011 and 2017 (includes corresponding Graph/Chart) 265
COMPETITIVE LANDSCAPE
Total Companies Profiled: 204 (including Divisions/Subsidiaries - 210)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 132
Canada 10
Japan 3
Europe 56
France 9
Germany 7
The United Kingdom 17
Italy 1
Rest of Europe 22
Asia-Pacific (Excluding Japan) 4
Middle-East 5
------------------------------------------
Contents:
Biomarkers market worldwide is on the growth path, thanks to ever-increasing use of biomarkers in the area of medicine. Biomarkers also offer tremendous support in effective clinical decision making, which is mainly dependent on diagnosing the health status of a patient. Biomarkers are increasingly finding application in the diagnosis of various diseases, especially cancer. The cancer diagnosis area has been witnessing the emergence of novel tools aimed at expediting discovery of cancer biomarkers. Additionally, proteomics is increasingly making its presence felt in the biomarker discovery as well as testing arena, which in turn is fuelling demand for related services. Further, with growing popularity of biomarkers, an increasing number of pharmaceutical companies are using biomarkers in their drug development efforts. Alongside, a few industrial companies have totally dedicated their research efforts for identifying and discovering biomarkers. The global economic downturn failed to have any detrimental effect on the biomarkers market worldwide. Global market for biomarkers continued to surge ahead at double-digit growth rate even during the recession period.
Lately, the global biomarkers market is witnessing the emergence of several new companies. The market has been registering significant collaboration deals among companies, which is resulting in a growing application base for biomarkers in the drug discovery and diagnosis domains. New companies are likely to provide advanced technology platforms in areas such as proteomics, transcriptomics, pharmacogenomics and others, which aid in discovering, developing and qualifying biomarkers.
On the flip side, huge capital investment involved in biomarker discovery, development and application is a major factor hampering growth in the market. Furthermore, the process of biomarker validation is highly expensive as it uses high sensitivity tools. These factors are likely to force certain small organizations and Contract Research Organizations (CROs) to completely exclude the use of biomarkers. In addition, biomarker validation tests also increase complexity of the process of drug development, affecting overall biomarker market. As such, success in the area of biomarkers demands substantial contributions from all those involved in the development of biomarkers. The various regulatory agencies in the world are working towards establishing appropriate framework and guidelines for accessing biomarker data. These efforts of the regulating bodies are likely to encourage the adoption of the new technology by companies in the diagnostic and pharmaceutical sectors, in the coming years.
The market is, however, witnessing growth in the number of new service providers and companies. These new companies offer potential to provide several pioneering chemogenomic, bioinformatics, genomic, metabolomic, transcriptomic, peptidomic, glycoproteomic, proteomic and pharmacogenomic technology platforms that target biomarker qualification, discovery, and development. The advancements in this segment is likely to be a key driver for further biomarker research that would increase sample throughput, enhance detection levels and bring about multiple biomarker panels’ multiplex detection that gains utility in diagnostic’s preclinical research, clinical trials and commercialization processes.
Region-wise, the US constitutes the largest market for biomarkers, as stated by Global Industry Analysts's new market research report on Biomarkers. Strengths provided by biomarkers in facilitating successful identification/validation of target further boosted the speed at which drugs are developed and this proved to be a growth promoter for the biomarker market in the US. Other important factors positively influencing the biomarker market in the US, and North American market as a whole, include an increasing demand for superior disease diagnostic and therapeutic capabilities from aging population, a higher technology adoption rate, and an increasing market requirement for biomarkers in drug development and discovery. Asia-Pacific is likely to emerge as the fastest growing market with a CAGR of 28% over the analysis period. A key factor fueling market growth in Asia is the ever-growing information technology industry in the region. The biomarker technologies sector in Asia-pacific is experiencing a healthy growth on account of excellent uptake of the novel methods for disease treatment and diagnosis.
Biomarker Discovery represents the largest area of application for Biomarkers. Biomarker Research, though currently in nascent stage, has achieved significant progress in the development of diagnostics and therapeutics targeting cancer. The technology’s capabilities to increase productivity by detecting the most appropriate drug candidate in the early R&D process offers significant potential in other disease areas as well.
Clinical Drug Development is likely to emerge as the fastest growing area of application, registering a CAGR of 26.5% over the analysis period. Use of Biomarkers in Clinical Drug Development is gaining rapid momentum and several global players are employing biomarkers in their drug development procedures as they significantly increase the efficacy of the process. Nearly 90% of candidate compounds fail in clinical trials mainly due to factors related to toxicity, absorption and metabolism among others. Biomarkers serve as important tools in detecting possibilities of drug failure at an early stage and thereby prevent substantial losses.
Oncology occupies a lion’s share of the global Biomarkers market in terms of therapeutics. Cancer biomarkers play a critical role in analyzing characteristics of the disease, which enable delivery of effective therapies. Cancer biomarkers offers several applications such as therapy selection, early detection and prognosis treatment. Cancer emerged as a leading diagnostic application of biomarkers worldwide, due primarily to growing number of cancer biomarkers receiving regulatory clearances. Cardiology is expected to emerge as the fastest growing segment in terms of therapeutics with a CAGR of about 24% over the analysis period. A major factor driving growth in the global cardiovascular biomarker market is the ability of these biomarkers to make accurate prediction of heart failure in stable patients. Besides, these biomarkers are also capable of accurately assessing risks of ACS, stroke and other cardiovascular events in home as well as primary care settings.
Global Industry Analysts ©
Lately, the global biomarkers market is witnessing the emergence of several new companies. The market has been registering significant collaboration deals among companies, which is resulting in a growing application base for biomarkers in the drug discovery and diagnosis domains. New companies are likely to provide advanced technology platforms in areas such as proteomics, transcriptomics, pharmacogenomics and others, which aid in discovering, developing and qualifying biomarkers.
On the flip side, huge capital investment involved in biomarker discovery, development and application is a major factor hampering growth in the market. Furthermore, the process of biomarker validation is highly expensive as it uses high sensitivity tools. These factors are likely to force certain small organizations and Contract Research Organizations (CROs) to completely exclude the use of biomarkers. In addition, biomarker validation tests also increase complexity of the process of drug development, affecting overall biomarker market. As such, success in the area of biomarkers demands substantial contributions from all those involved in the development of biomarkers. The various regulatory agencies in the world are working towards establishing appropriate framework and guidelines for accessing biomarker data. These efforts of the regulating bodies are likely to encourage the adoption of the new technology by companies in the diagnostic and pharmaceutical sectors, in the coming years.
The market is, however, witnessing growth in the number of new service providers and companies. These new companies offer potential to provide several pioneering chemogenomic, bioinformatics, genomic, metabolomic, transcriptomic, peptidomic, glycoproteomic, proteomic and pharmacogenomic technology platforms that target biomarker qualification, discovery, and development. The advancements in this segment is likely to be a key driver for further biomarker research that would increase sample throughput, enhance detection levels and bring about multiple biomarker panels’ multiplex detection that gains utility in diagnostic’s preclinical research, clinical trials and commercialization processes.
Region-wise, the US constitutes the largest market for biomarkers, as stated by Global Industry Analysts's new market research report on Biomarkers. Strengths provided by biomarkers in facilitating successful identification/validation of target further boosted the speed at which drugs are developed and this proved to be a growth promoter for the biomarker market in the US. Other important factors positively influencing the biomarker market in the US, and North American market as a whole, include an increasing demand for superior disease diagnostic and therapeutic capabilities from aging population, a higher technology adoption rate, and an increasing market requirement for biomarkers in drug development and discovery. Asia-Pacific is likely to emerge as the fastest growing market with a CAGR of 28% over the analysis period. A key factor fueling market growth in Asia is the ever-growing information technology industry in the region. The biomarker technologies sector in Asia-pacific is experiencing a healthy growth on account of excellent uptake of the novel methods for disease treatment and diagnosis.
Biomarker Discovery represents the largest area of application for Biomarkers. Biomarker Research, though currently in nascent stage, has achieved significant progress in the development of diagnostics and therapeutics targeting cancer. The technology’s capabilities to increase productivity by detecting the most appropriate drug candidate in the early R&D process offers significant potential in other disease areas as well.
Clinical Drug Development is likely to emerge as the fastest growing area of application, registering a CAGR of 26.5% over the analysis period. Use of Biomarkers in Clinical Drug Development is gaining rapid momentum and several global players are employing biomarkers in their drug development procedures as they significantly increase the efficacy of the process. Nearly 90% of candidate compounds fail in clinical trials mainly due to factors related to toxicity, absorption and metabolism among others. Biomarkers serve as important tools in detecting possibilities of drug failure at an early stage and thereby prevent substantial losses.
Oncology occupies a lion’s share of the global Biomarkers market in terms of therapeutics. Cancer biomarkers play a critical role in analyzing characteristics of the disease, which enable delivery of effective therapies. Cancer biomarkers offers several applications such as therapy selection, early detection and prognosis treatment. Cancer emerged as a leading diagnostic application of biomarkers worldwide, due primarily to growing number of cancer biomarkers receiving regulatory clearances. Cardiology is expected to emerge as the fastest growing segment in terms of therapeutics with a CAGR of about 24% over the analysis period. A major factor driving growth in the global cardiovascular biomarker market is the ability of these biomarkers to make accurate prediction of heart failure in stable patients. Besides, these biomarkers are also capable of accurately assessing risks of ACS, stroke and other cardiovascular events in home as well as primary care settings.
Global Industry Analysts ©
Companies Mentioned
- Abbott Laboratories
- Affymetrix Inc.
- Agilent Technologies Inc.
- Alexion Pharmaceuticals
- Beckman Coulter Inc.
- Becton
- Dickinson and Company
- Bio-Rad Laboratories Inc.
- BioMérieux
- Bruker Corporation
- Caprion Proteomics Inc.
- Clarient Inc.
- Compugen Ltd.
- Correlogic Systems Inc.
- DiagnoCure Inc.
- Epigenomics AG
- GE Healthcare
- Gene Logic
- Genedata AG
- Gen-Probe Inc.
- GlaxoSmithKline Plc
- Hitachi Medical Corporation
- Illumina Inc.
- LabCorp.
- Life Technologies Corporation
- Merck & Co. Inc.
- Metabolon Inc.
- Myriad Genetics Inc.
- Novartis International AG
- Panacea Laboratories
- Pfizer Inc.
- Philips Healthcare
- QIAGEN NV
- Quest Diagnostics Inc.
- Roche Diagnostics Corp.
- Rubicon Genomics Inc.
- Rules-Based Medicine Inc.
- Siemens Healthcare Diagnostics Inc.
- Affymetrix Inc.
- Agilent Technologies Inc.
- Alexion Pharmaceuticals
- Beckman Coulter Inc.
- Becton
- Dickinson and Company
- Bio-Rad Laboratories Inc.
- BioMérieux
- Bruker Corporation
- Caprion Proteomics Inc.
- Clarient Inc.
- Compugen Ltd.
- Correlogic Systems Inc.
- DiagnoCure Inc.
- Epigenomics AG
- GE Healthcare
- Gene Logic
- Genedata AG
- Gen-Probe Inc.
- GlaxoSmithKline Plc
- Hitachi Medical Corporation
- Illumina Inc.
- LabCorp.
- Life Technologies Corporation
- Merck & Co. Inc.
- Metabolon Inc.
- Myriad Genetics Inc.
- Novartis International AG
- Panacea Laboratories
- Pfizer Inc.
- Philips Healthcare
- QIAGEN NV
- Quest Diagnostics Inc.
- Roche Diagnostics Corp.
- Rubicon Genomics Inc.
- Rules-Based Medicine Inc.
- Siemens Healthcare Diagnostics Inc.
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Thursday, May 23, 2013
12:08:25 PM
12:08:25 PM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Biomarkers - Global Strategic Business Report
Web Address
http://www.researchandmarkets.com/reports/1882099
Office Code
OC8DIQSOOPNPYX
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic (PDF) - Single User |
|
EURO€ 4,248.00 |
|---|---|---|
| Electronic (PDF) - 1 - 15 Users |
|
EURO€ 10,195.00 |
| Electronic (PDF) - 1 - 5 Users |
|
EURO€ 5,947.00 |
| Electronic (PDF) - 1 - 10 Users |
|
EURO€ 8,071.00 |
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Thursday, May 23, 2013
12:08:25 PM
12:08:25 PM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp